Cargando…

Neutralizing antibody titres in SARS-CoV-2 infections

The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Eric H. Y., Tsang, Owen T. Y., Hui, David S. C., Kwan, Mike Y. W., Chan, Wai-hung, Chiu, Susan S., Ko, Ronald L. W., Chan, Kin H., Cheng, Samuel M. S., Perera, Ranawaka A. P. M., Cowling, Benjamin J., Poon, Leo L. M., Peiris, Malik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782739/
https://www.ncbi.nlm.nih.gov/pubmed/33397909
http://dx.doi.org/10.1038/s41467-020-20247-4
_version_ 1783631966640275456
author Lau, Eric H. Y.
Tsang, Owen T. Y.
Hui, David S. C.
Kwan, Mike Y. W.
Chan, Wai-hung
Chiu, Susan S.
Ko, Ronald L. W.
Chan, Kin H.
Cheng, Samuel M. S.
Perera, Ranawaka A. P. M.
Cowling, Benjamin J.
Poon, Leo L. M.
Peiris, Malik
author_facet Lau, Eric H. Y.
Tsang, Owen T. Y.
Hui, David S. C.
Kwan, Mike Y. W.
Chan, Wai-hung
Chiu, Susan S.
Ko, Ronald L. W.
Chan, Kin H.
Cheng, Samuel M. S.
Perera, Ranawaka A. P. M.
Cowling, Benjamin J.
Poon, Leo L. M.
Peiris, Malik
author_sort Lau, Eric H. Y.
collection PubMed
description The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT(90)) and 50% (PRNT(50)) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT(50) titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT(50) antibody titres to decrease by half (T(1/2)) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT(90) and PRNT(50) antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals.
format Online
Article
Text
id pubmed-7782739
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-77827392021-01-11 Neutralizing antibody titres in SARS-CoV-2 infections Lau, Eric H. Y. Tsang, Owen T. Y. Hui, David S. C. Kwan, Mike Y. W. Chan, Wai-hung Chiu, Susan S. Ko, Ronald L. W. Chan, Kin H. Cheng, Samuel M. S. Perera, Ranawaka A. P. M. Cowling, Benjamin J. Poon, Leo L. M. Peiris, Malik Nat Commun Article The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT(90)) and 50% (PRNT(50)) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT(50) titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT(50) antibody titres to decrease by half (T(1/2)) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT(90) and PRNT(50) antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals. Nature Publishing Group UK 2021-01-04 /pmc/articles/PMC7782739/ /pubmed/33397909 http://dx.doi.org/10.1038/s41467-020-20247-4 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lau, Eric H. Y.
Tsang, Owen T. Y.
Hui, David S. C.
Kwan, Mike Y. W.
Chan, Wai-hung
Chiu, Susan S.
Ko, Ronald L. W.
Chan, Kin H.
Cheng, Samuel M. S.
Perera, Ranawaka A. P. M.
Cowling, Benjamin J.
Poon, Leo L. M.
Peiris, Malik
Neutralizing antibody titres in SARS-CoV-2 infections
title Neutralizing antibody titres in SARS-CoV-2 infections
title_full Neutralizing antibody titres in SARS-CoV-2 infections
title_fullStr Neutralizing antibody titres in SARS-CoV-2 infections
title_full_unstemmed Neutralizing antibody titres in SARS-CoV-2 infections
title_short Neutralizing antibody titres in SARS-CoV-2 infections
title_sort neutralizing antibody titres in sars-cov-2 infections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782739/
https://www.ncbi.nlm.nih.gov/pubmed/33397909
http://dx.doi.org/10.1038/s41467-020-20247-4
work_keys_str_mv AT lauerichy neutralizingantibodytitresinsarscov2infections
AT tsangowenty neutralizingantibodytitresinsarscov2infections
AT huidavidsc neutralizingantibodytitresinsarscov2infections
AT kwanmikeyw neutralizingantibodytitresinsarscov2infections
AT chanwaihung neutralizingantibodytitresinsarscov2infections
AT chiususans neutralizingantibodytitresinsarscov2infections
AT koronaldlw neutralizingantibodytitresinsarscov2infections
AT chankinh neutralizingantibodytitresinsarscov2infections
AT chengsamuelms neutralizingantibodytitresinsarscov2infections
AT pereraranawakaapm neutralizingantibodytitresinsarscov2infections
AT cowlingbenjaminj neutralizingantibodytitresinsarscov2infections
AT poonleolm neutralizingantibodytitresinsarscov2infections
AT peirismalik neutralizingantibodytitresinsarscov2infections